NASDAQ: NVCN
TSX: NVC
VANCOUVER, Nov. 2, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or
the "Company") (NASDAQ: NVCN) (TSX: NVC) announced today its notable presentations at the annual Transcatheter
Cardiovascular Therapeutics (TCT) symposium, the world's largest educational meeting specializing in interventional cardiovascular
medicine held in Washington, DC.
On October 31, Dr. Anson Cheung from St.
Paul's hospital, Vancouver, Canada presented an update on the ongoing Tiara™ program. He
presented the clinical data to date, on the 19 patients treated with the Tiara™ valve. The 30-day survival rate for these 19
patients is 84%. Overall, the data presented was very encouraging, in this very sick cohort of patients treated with
Tiara.
Dr. Cheung elaborated that enrolment continues in the TIARA-I Early Feasibility Trial and in other compassionate use programs.
The TIARA-I trial is assessing the safety and performance of the Tiara™ mitral valve system and the implantation procedure in
high-risk patients suffering from severe mitral regurgitation.
Dr. Florian Deuschl from Hamburg, Germany gave a presentation
entitled, Echocardiographic Guiding of a Novel Mitral Valve Replacement, which reviewed his positive experience from the Tiara
implantation cases performed by the team in Hamburg.
With respect to the Company's other cardiovascular device, the Neovasc Reducer™, for the treatment of Refractory Angina, Dr.
Gregg Stone presented the Reducer as the most effective treatment option for patients suffering from
refractory angina despite optimal medical therapy. He reviewed the results of the COSIRA randomized study which was published
in the New England Journal of Medicine last year. He also outlined the design of the COSIRA II, pivotal US trial, which will
include 380 patients and will be a multicenter prospective, randomized, double-blind, sham-controlled trial.
In addition, during the conference there were two posters presented from Italy, describing the
positive effect of the Neovasc Reducer™.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products in development include the Tiara™, for the transcatheter treatment of mitral valve
disease and the Neovasc Reducer™ for the treatment of refractory angina. The Company also sells a line of advanced biological
tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more
information, visit: www.neovasc.com.
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act
of 1995 and applicable Canadian securities laws, including statements that the study found Reducer implantation to be the most
effective treatment option for patients suffering from refractory angina despite optimal medical therapy and the proposed design of
the COSIRA II pivotal US trial. The words "most effective" and "will" are intended to identify these forward-looking
statements. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience
and its perception of historical trends, current conditions and expected future developments, as well as other factors that the
Company believes are appropriate in the circumstances. Many factors and assumptions could cause the Company's actual results,
performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including,
without limitation, potential changes in circumstances relating to the Company's financing requirements, whether as a result of
unforeseen circumstances or otherwise; the conduct or possible outcomes of any actual or threatened legal proceedings, including
any post-trial motions or appeals, which are inherently uncertain; the potential benefits of the Neovasc Reducer™ and Tiara™ as
compared with other products; successful enrollment of patients in studies and trials for the Neovasc Reducer™ and Tiara™; results
of the trials and studies for the Neovasc Reducer™ and Tiara™ that meet the Company's expectations; the Company's receipt of any
required local and institutional regulatory approvals and the timing and costs of obtaining such approvals; European enrollment in
our clinical trials, studies and compassionate use cases and the success of applications in Europe; the Company's ability to
protect its intellectual property; the Company's ability to raise additional funding; changes in business strategy or development
plans; existing governmental regulations and changes in, or the failure to comply with, governmental regulations and general
economic and business conditions, both nationally and in the regions in which the Company operates. These risk factors and others
relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Information Form,
which is included in its Annual Report on Form 40-F (copies of which filings may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and
readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and
undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as required by law.
SOURCE Neovasc Inc.
